Open an account

Aptevo Therapeutics

APVO · NASDAQ

$1.62+$0.015 (+0.94%)TodayMarket closed ·
Prev close $1.60

About APVO

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 33 full-time employees. The company went IPO on 2016-07-20. The firm has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The firm has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.

Employees
33
Headquarters
Seattle, Washington
Listed
Jul 20, 2016
Sector
Health Care
Industry
Biotechnology
Website
aptevotherapeutics.com

APVO key statistics

Market cap
2.92M
Price-earnings ratio
0.02
Dividend yield
—
Average volume
40.29K
Volume
12.57K
Open price
$1.61
High today
$1.65
Low today
$1.60
52 Week high
$29.70
52 Week low
$1.37

Aptevo Therapeutics (APVO) at a glance

As of Oct 20, 2026, Aptevo Therapeutics (APVO) shares are priced at $1.62, giving the company a market cap of 2.92M and a price-to-earnings ratio of 0.02.

Today the stock has traded between $1.60 and $1.65. The current price is 0.9% above the day's low and 2.1% below its high.

Volume so far is 12.57K shares, below the average of 40.29K shares a day.

Over the past year Aptevo Therapeutics has ranged from $1.37 to $29.70, and now sits 1% of the way up that range.

Aptevo Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$5.31 per share against an estimate of -$6.14.

APVO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 60.4% on average.

  1. Q3 FY24: reported -$6,393.60 per share against an estimate of -$45,582.37
  2. Q4 FY24: reported -$29,653.20 per share against an estimate of -$2,845.80
  3. Q1 FY25: reported -$1,580.40 per share against an estimate of -$1,545.91
  4. Q2 FY25: reported -$151.20 per share against an estimate of -$1,527.55
  5. Q3 FY25: reported -$33.48 per share against an estimate of -$38.37
  6. Q4 FY25: reported -$0.01 per share against an estimate of -$8.25
  7. Q1 FY26: reported -$6.41 per share against an estimate of -$5.71
  8. Q2 FY26: reported -$5.31 per share against an estimate of -$6.14

APVO news

  • Vandana Singh

    Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Alex Perry

    What's Going On With Aptevo Therapeutics Stock Today?

  • Avi Kapoor

    US Stocks Mixed; Biohaven Shares Fall

  • Avi Kapoor

    Gold Falls Over 1%; Darden Posts Downbeat Earnings

  • Avi Kapoor

    Nasdaq Surges 100 Points; Bionano Genomics Shares Plunge

  • Market-Moving News for September 18th

  • Benzinga Bulls And Bears: Circle, Sunrun, JetBlue — And Mideast Has Markets Nervous

Similar companies

Companies in the same industry as Aptevo Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.